Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year

BACKGROUND: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. METHODS: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadaru, Tarun, Shibli-Rahhal, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Bone and Mineral Research 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973401/
https://www.ncbi.nlm.nih.gov/pubmed/33730783
http://dx.doi.org/10.11005/jbm.2021.28.1.51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973401/
https://www.ncbi.nlm.nih.gov/pubmed/33730783
http://dx.doi.org/10.11005/jbm.2021.28.1.51

Ejemplares similares